DRTS vs DSGN

Alpha Tau Medical Ltd. vs Design Therapeutics, Inc. — Valuation Comparison 2026

DRTS

Biotechnology
Alpha Tau Medical Ltd.
Quality
2.3
out of 10
Value Trap
6
SAFE
Price
$10.13
Last close
Models
7/13
Active
VS

DSGN

Biotechnology
Design Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$10.74
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DRTS Fair ValueDRTS Upside DSGN Fair ValueDSGN Upside
Bayesian DCF Intrinsic $2.66 -73.7% $2.99 -72.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.08 -99.0% $0.57 -94.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $10.17 -1.2% $10.40 -3.2%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRTS vs DSGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRTS vs DSGN — Which Stock Is More Undervalued?

DSGN scores higher with a 4.1/10 quality rating vs DRTS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alpha Tau Medical Ltd. (DRTS) and Design Therapeutics, Inc. (DSGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRTS currently trades at $10.13 with a QOC of 2.3/10, while DSGN trades at $10.74 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).